April and baff inhibitory immunomodulatory proteins and methods of use thereof
By designing truncated TACI peptides and substituting amino acids, the binding with APRIL and BAFF is enhanced, while the binding with BCMA or TACI is blocked. This solves the problem of effectively regulating B cell immune responses in existing technologies and achieves therapeutic effects on a variety of immune diseases.
CN122277700APending Publication Date: 2026-06-26ALPINE IMMUNE SCIENCES INC
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ALPINE IMMUNE SCIENCES INC
- Filing Date
- 2021-05-07
- Publication Date
- 2026-06-26
Smart Images
Figure CN122277700A_ABST
Abstract
This invention relates to APRIL and BAFF inhibitory immunomodulatory proteins and methods of using them, specifically providing immunomodulatory proteins exhibiting neutralizing activity against BAFF and APRIL (or BAFF / APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of transmembrane activators and CAML interactors (TACI). The provided immunomodulatory proteins include TACI-Fc fusion proteins. Nucleic acid molecules encoding said immunomodulatory proteins are also provided. The immunomodulatory proteins provide therapeutic efficacy against a variety of immune diseases, disorders, or conditions. Compositions and methods for preparing and using such proteins are also provided.
Need to check novelty before this filing date? Find Prior Art